Grant: Engage Grants Program
McGill University
$25,000.00
Development of DNA-Based Nanoparticles (DNP) for the Targeted Delivery of Therapeutics to Cancer Cells
FY 2016-17
Summary
Chemotherapy drugs have made life-saving advances in cancer treatment, yet patients are still at risk for a hostof negative side-effects. Although these therapies are designed to kill cancer cells, they often end up poisoninghealthy cells, leading to side-effects and drug resistance partially due to the high dosage and delivery methodused. Using host-guest chemical strategies, unsuitable formulations for drug delivery can be modifiedsufficiently to cross the buccal mucosa barrier and enter the blood stream which could enhance therapeuticefficacy. Intelgenx (IGX) will expand the applicability of buccal delivery through the development of newinnovative host-guest drug delivery methods using DNA nanoparticles and sequence polymers. This proposalaims to overcome current delivery limitations by expanding the repertoire of delivery vehicles and formulationsusing three-dimensional (3D) DNA structures. They are precisely controlled in size, shape and programmedpositioning of units on their surface. This new class of high-performance materials will be designed for ease ofFDA approval, facilitating timely translation to a clinical setting. We propose that DNA structures along withnovel packaging techniques, such as VersaFilm (developed by IGX) can be used as a platform that selectivelytargets different types of cancer cells, makes them respond to chemotherapy, and increases their chances ofachieving cancer cellular death. Our proposed research plan will use a systematic approach, which addresseseach of the major obstacles that a drug delivery vehicle encounters as it circulates in the body to reach itstarget. The proposed studies will be important in the field of drug delivery, because they will provide designguidelines for researchers, to optimize the ability of delivery vehicles to reach their target unhindered. We aimto develop delivery vehicles that are biologically compatible, biodegradable and can deliver drugs selectivelyinto cancer cells. Moreover, leveraging DNA nanoparticles for developing novel formulations will expand theavailable routes for drug delivery and enhance existing therapeutics and is of significant benefit to bothpharmaceutical and healthcare professionals in Canada.
Program
Engage Grants Program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
507214-2016
Name nom
Sleiman, Hanadi
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5300
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Molecular biology
Research subject fr
Biologie moléculaire
Partie
1
Nb partie
1
Application title
Development of DNA-Based Nanoparticles (DNP) for the Targeted Delivery of Therapeutics to Cancer Cells
Keyword
NSERC
Application summary
Chemotherapy drugs have made life-saving advances in cancer treatment, yet patients are still at risk for a hostof negative side-effects. Although these therapies are designed to kill cancer cells, they often end up poisoninghealthy cells, leading to side-effects and drug resistance partially due to the high dosage and delivery methodused. Using host-guest chemical strategies, unsuitable formulations for drug delivery can be modifiedsufficiently to cross the buccal mucosa barrier and enter the blood stream which could enhance therapeuticefficacy. Intelgenx (IGX) will expand the applicability of buccal delivery through the development of newinnovative host-guest drug delivery methods using DNA nanoparticles and sequence polymers. This proposalaims to overcome current delivery limitations by expanding the repertoire of delivery vehicles and formulationsusing three-dimensional (3D) DNA structures. They are precisely controlled in size, shape and programmedpositioning of units on their surface. This new class of high-performance materials will be designed for ease ofFDA approval, facilitating timely translation to a clinical setting. We propose that DNA structures along withnovel packaging techniques, such as VersaFilm (developed by IGX) can be used as a platform that selectivelytargets different types of cancer cells, makes them respond to chemotherapy, and increases their chances ofachieving cancer cellular death. Our proposed research plan will use a systematic approach, which addresseseach of the major obstacles that a drug delivery vehicle encounters as it circulates in the body to reach itstarget. The proposed studies will be important in the field of drug delivery, because they will provide designguidelines for researchers, to optimize the ability of delivery vehicles to reach their target unhindered. We aimto develop delivery vehicles that are biologically compatible, biodegradable and can deliver drugs selectivelyinto cancer cells. Moreover, leveraging DNA nanoparticles for developing novel formulations will expand theavailable routes for drug delivery and enhance existing therapeutics and is of significant benefit to bothpharmaceutical and healthcare professionals in Canada.